Breaking News Headlines Today | Ground News

See every side of every news story

centerforbiosimilars.com image

News from centerforbiosimilars.com

All of today’s top news stories from centerforbiosimilars.com. Get the full analysis behind how media bias impacts breaking news.

Ground News has come across 62 headlines reported on by centerforbiosimilars.com during the past 3 months.

Ground News rates centerforbiosimilars.com’s media bias as unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

centerforbiosimilars.com’s aggregated factuality score is Unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about centerforbiosimilars.com

Where is centerforbiosimilars.com located?centerforbiosimilars.com's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top centerforbiosimilars.com News

Insulin Aspart-xjhz Becomes First Interchangeable Biosimilar Rapid-Acting Insulin

United States · United States

Insulin Aspart-xjhz Becomes First Interchangeable Biosimilar Rapid-Acting Insulin

The agent, Kirsty, represents a more affordable alternative to Novolog.See the Story

3 Types of Multiple Myeloma Treatments

United States · United States

3 Types of Multiple Myeloma Treatments

Medically reviewed by Archana Sharma, DOThere are several treatment options for multiple myeloma. Since this disease varies by person, the type of therapy you receive depends on factors such as your age, general health, and disease stage.Jump to Key Takeaways.nomadnes / Getty Images The goal of multiple myeloma treatment is to control the cancer, ease symptoms, and extend life.1. Drug TherapyMost people with multiple myeloma begin treatment with…See the Story

Medicare Price Negotiations Will Slow Biosimilar Momentum, Widening Market Gap

Inflation Reduction Act · United States

Medicare Price Negotiations Will Slow Biosimilar Momentum, Widening Market Gap

Government price negotiations under the Inflation Reduction Act may hinder biosimilar development, impacting drug costs and patient access to affordable therapies.Read Article

FDA-Approved Denosumab Biosimilars Expand Oncology Options in US

Celltrion USA launches 2 denosumab biosimilars, Stoboclo and Osenvelt, enhancing treatment options for osteoporosis and cancer-related skeletal issues.United States · United States See the Story

BioRationality: How the FDA Can Bypass Congress to Change Biosimilar Guidance

The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and emerging treatment paradigms.United States · United States Read Article

Dispelling Doubts: Review Affirms Safety, Efficacy of Biosimilar Insulins

A recent review confirms the safety and efficacy of biosimilar insulins, addressing concerns and promoting their adoption for diabetes treatment.Diabetes Read Article

Consumers and Providers Face Biosimilar Knowledge Hurdles

Significant knowledge gaps about biosimilars persist among consumers and healthcare professionals, hindering their adoption and potential benefits in health care.Health Care Read Article

Real-World Data Shows Similar Clinical Outcomes in Patients Receiving Biosimilars Following Switch From Reference Product

Real-world data shows patients switching from Humira to biosimilars Hadlima and Hyrimoz achieve similar outcomes without hospitalization.Australia · Australia See the Story

Biosimilar SB12 Matches Eculizumab in PNH Treatment Across Diverse Patient Groups

Biosimilar SB12 demonstrated comparable efficacy and safety for paroxysmal nocturnal hemoglobinuria (PNH) to its reference drug, showing similar outcomes across diverse patient groups.Read Article

Adalimumab Double Take: The Unexpected Return to Reference Humira

About 13% of patients who switch from Humira to an adalimumab biosimilar switch back to the originator, according to research from Truveta. However, the presented data may not tell the full story.Read Article

Biocon's Breakthrough: Yesafili Gets Green Light in Canada

67% Left coverage: 9 sources

Biocon Biologics has received Health Canada's approval for Yesafili, a biosimilar injection for eye ailments. As the first Eylea biosimilar approved in Canada, Yesafili's launch is set for July 4, 2025. This milestone highlights Biocon's commitment to affordable, high-quality biologics worldwide.Health Canada · Toronto See the Story

Breaking News Topics Related to centerforbiosimilars.com